文献速递临床试验与 GCP

N-乙酰半胱氨酸在重症COVID-19患者中的疗效:一项随机对照试验研究方案的结构化摘要

The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2021-04-12

该研究为前瞻性、随机、单盲、3期对照临床试验,计划纳入40例重症COVID-19患者,按1:1随机分为干预组(标准治疗+N-乙酰半胱氨酸300 mg/kg单次缓慢静脉注射)和对照组(标准治疗+安慰剂)。主要终点为ICU住院时间与患者临床状况的复合终点,在基线及干预后第14天或出院日评估。

要点

  • N-乙酰半胱氨酸除黏液溶解作用外,其抗氧化效应可能有助于重症COVID-19患者恢复。
  • 干预组在标准治疗基础上接受N-乙酰半胱氨酸300 mg/kg(相当于20 g)单次缓慢静脉注射。
  • 主要终点为ICU住院时间与临床状况的复合终点,评估至第14天或出院日。

核心结论

  • 该研究旨在评估N-乙酰半胱氨酸对重症COVID-19患者的疗效,目前仅为研究方案摘要,尚未报告结果。

研究设计与样本

  • 前瞻性、随机、单盲、3期对照临床试验,两组平行设计,比例1:1,共计划纳入40例患者。
  • 干预组20例接受标准治疗加N-乙酰半胱氨酸,对照组20例接受标准治疗加安慰剂。
  • 采用在线网络工具按置换区组随机化方法进行随机分组,并对随机序列分配进行隐藏。
  • 参与者不知晓分组,但主要研究者、医护人员、数据收集者和结局评估者知晓分组。

关键数值与推荐

  • 纳入标准:重症COVID-19患者且至少符合以下五项条件之一:呼吸频率>30次/分;低氧血症(氧饱和度或动脉血氧分压比<300);24-48小时内肺部浸润>50%肺面积;乳酸脱氢酶>245 U/L;进行性淋巴细胞减少。
  • 纳入患者需入住Shahid Mohammadi医院ICU,SARS-CoV-2 PCR检测阳性并签署书面知情同意。
  • 排除标准:对N-乙酰半胱氨酸过敏史、妊娠或拒绝参与研究。
  • 干预组:标准治疗加N-乙酰半胱氨酸(EXI-NACE 200mg/mL,10mL安瓿)300 mg/kg(相当于20 g)于住院第一天单次缓慢静脉注射。
  • 对照组:标准治疗加安慰剂(注射用无菌水,相同剂量),安慰剂外观与N-乙酰半胱氨酸注射液相同。

临床怎么用

  • 该方案为重症COVID-19患者使用N-乙酰半胱氨酸提供了随机对照试验框架,结果待报告后指导临床决策。

局限性

  • 样本量较小(40例),可能限制统计效能和结果外推。
  • 采用单盲设计,主要研究者和结局评估者知晓分组,可能引入偏倚。
  • 研究方案摘要未报告实际结果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Severe acute respiratory infection (SARI) caused by the SARS-CoV-2 virus may cause lung failure and the need for mechanical ventilation. Infection with SARS-COV-2 can lead to activation of inflammatory factors, increased reactive oxygen species, and cell damage. In addition to mucolytic effects, N-Acetylcysteine has antioxidant effects that we believe can help patients recover. In this study, we evaluate the efficacy of N-Acetylcysteine in patients with severe COVID-19. TRIAL DESIGN: This is a prospective, randomized, single-blinded, phase 3 controlled clinical trial with two arms (ratio 1:1) parallel-group design of 40 patients, using the placebo in the control group. PARTICIPANTS: All severe COVID-19 patients with at least one of the following five conditions: (respiration rate > 30 per minute), hypoxemia (O2 ≤ saturation, arterial oxygen partial pressure ratio <300), pulmonary infiltration (> 50% of lung area during 24 48 h), Lactate dehydrogenase (LDH) > 245 U / l, Progressive lymphopenia, and admitted to the intensive care unit of Shahid Mohammadi Hospital in Bandar Abbas and have positive PCR test results for SARS-Cov-2 and sign the written consent of the study will be included. Patients will be excluded from the study if they have a history of hypersensitivity to N-Acetylcysteine, pregnancy, or refuse to participate in the study. INTERVENTION AND COMPARATOR: After randomization, participants in the intervention group receive standard of care (SOC) according to the National Committee of COVID-19 plus N-acetylcysteine (EXI-NACE 200mg/mL, in 10mL ampules of saline for parenteral injection (EXIR pharmaceutical company)) at a dose of 300 mg/kg equivalent to 20 gr as a slow single intravenous injection on the first day of hospitalization. In the control group patients receive SOC and placebo ( Sterile water for injection as the same dose). The placebo is identical in appearance to the N-acetylcysteine injection (EXIR pharmaceutical company as well). MAIN OUTCOMES: The primary endpoint for this study is a composite endpoint for the length of hospitalization in the intensive care unit and the patient's clinical condition. These outcomes were measured at the baseline (before the intervention) and on the 14th day after the intervention or on the discharge day. RANDOMISATION: Eligible participants (40) will be randomized in two arms in the ratio of 1: 1 (20 per arm) using online web-based tools and by permuted block randomization method. To ensure randomization concealment, random sequence codes are assigned to patients by the treatment team at the time of admission without knowing that each code is in the intervention or comparator group. BLINDING (MASKING): All participants will be informed about participating in the study and the possible side effects of medication and placebo. Patients participating in the study will not be aware of the assignment to the intervention or control group. The principal investigator, health care personnel, data collectors, and those evaluating the outcome are aware of patient grouping. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 40 patients participate in this study, which are randomly divided; 20 patients in the intervention group will receive SOC and N-acetylcysteine, 20 patients in the control group will receive SOC and placebo. TRIAL STATUS: First version of the protocol was approved by the Deputy of Research and Technology and the ethics committee of Hormozgan University of Medical Sciences on February 14, 2021, with the local code 990573, and the recruitment started on March 2, 2021 and the expected recruitment end date is April 1, 2021. TRIAL REGISTRATION: The protocol was registered before starting participant recruitment entitled: Evaluation of the efficacy of N-Acetylcysteine in severe COVID-19 patients: a randomized controlled phase III clinical trial, IRCT20200509047364N3 , at Iranian Registry of clinical trials on 20 February 2021. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rahimi A, Samimagham HR, Azad MH, et al. The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 33845881. doi:10.1186/s13063-021-05242-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。